Benoit Barteau

Benoit Barteau serves as a Board Member for multiple biotechnology companies, including Eligo Bioscience, Flamingo Therapeutics, Tridek-One, Meiogenix, BrainEver, Alentis Therapeutics, and Igyxos, focusing on innovative therapies across various medical fields like microbiome modulation, RNA therapeutics, and chromosome editing. Benoit Barteau has extensive experience in the life sciences sector, holding a directorial position at Bpifrance overseeing multiple innovative funds. Educational qualifications include a PhD in Immunology from Nantes Université, a Master's in Finance from IAE Paris - Sorbonne Business School, and engineering studies in Biology and Biotechnology from Université de Technologie de Compiègne.